We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health (ELV) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest trading session, Elevance Health (ELV - Free Report) closed at $476.96, marking a -0.28% move from the previous day. This change lagged the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a rise of 0.18%, and the technology-dominated Nasdaq saw an increase of 1.37%.
The health insurer's stock has climbed by 5.54% in the past month, exceeding the Medical sector's gain of 2.68% and the S&P 500's gain of 4.39%.
The investment community will be paying close attention to the earnings performance of Elevance Health in its upcoming release. The company is predicted to post an EPS of $5.60, indicating a 7.07% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $41.97 billion, showing a 5.8% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $33.04 per share and a revenue of $169.83 billion, indicating changes of +13.66% and +9.1%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Elevance Health. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.01% fall in the Zacks Consensus EPS estimate. As of now, Elevance Health holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Elevance Health has a Forward P/E ratio of 14.48 right now. This signifies a discount in comparison to the average Forward P/E of 20.55 for its industry.
We can additionally observe that ELV currently boasts a PEG ratio of 1.2. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.66.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elevance Health (ELV) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Elevance Health (ELV - Free Report) closed at $476.96, marking a -0.28% move from the previous day. This change lagged the S&P 500's daily gain of 0.8%. Meanwhile, the Dow experienced a rise of 0.18%, and the technology-dominated Nasdaq saw an increase of 1.37%.
The health insurer's stock has climbed by 5.54% in the past month, exceeding the Medical sector's gain of 2.68% and the S&P 500's gain of 4.39%.
The investment community will be paying close attention to the earnings performance of Elevance Health in its upcoming release. The company is predicted to post an EPS of $5.60, indicating a 7.07% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $41.97 billion, showing a 5.8% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $33.04 per share and a revenue of $169.83 billion, indicating changes of +13.66% and +9.1%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Elevance Health. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.01% fall in the Zacks Consensus EPS estimate. As of now, Elevance Health holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Elevance Health has a Forward P/E ratio of 14.48 right now. This signifies a discount in comparison to the average Forward P/E of 20.55 for its industry.
We can additionally observe that ELV currently boasts a PEG ratio of 1.2. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.66.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.